• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Pfizer Q2 net dips to Rs 111 cr

expressbpdNovember 14, 2017

Tag: Pfizer , dips , Rs

Pfizer’s offer for the San Francisco, California-based Medivation goes far beyond the company’s market value of $11.1 billion. Medivation shares closed at $67.16 in Friday trading (Reuters)

Standalone revenue from operations rose to Rs 571.11 crore

Pfizer reported a 12 per cent dip in standalone net profit to Rs 111.15 crore for the quarter ended September 30, 2017. The company had posted a net profit of Rs 126.33 crore for the corresponding period of the previous fiscal, Pfizer said in a filing to BSE.

Standalone revenue from operations rose to Rs 571.11 crore as against Rs 557.66 crore for the same period year ago.

Previous:Life Science Giant PPD Cuts an Undisclosed Number of Jobs

Next:Laurus Labs’ net profit at Rs 48.8 crore in Q2 FY18

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Pfizer Q2 net dips to Rs 111 cr | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

TCU of Cooling circulators -25 UP TO 200 degree SUNDI-225 With explosion-proof cabinst

TCU of Cooling circulators -25 UP TO 200 degree SUNDI-225 With explosion-proof cabinst
CSJ Series Coarse Crusher

CSJ Series Coarse Crusher
MDI canisters

MDI canisters
DABCYL-Lys-HCoV-SARS

DABCYL-Lys-HCoV-SARS
Celastrus angulatus Celasturs angulatus Maxim angulatus maxim extract

Celastrus angulatus Celasturs angulatus Maxim angulatus maxim extract
Membrane Filters leakage Tester

Membrane Filters leakage Tester
Single-axis Dispersing Machine

Single-axis Dispersing Machine
Persulfates

Persulfates
Ioversol

Ioversol
(RS)-3-amino-2-(4-chlorophenyl)propylsulfonic acid；Saclofen

(RS)-3-amino-2-(4-chlorophenyl)propylsulfonic acid；Saclofen

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service